NASDAQ:SLS SELLAS Life Sciences Group (SLS) Stock Price, News & Analysis $1.19 -0.04 (-3.25%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$1.16▼$1.2450-Day Range$1.08▼$1.3952-Week Range$0.50▼$1.90Volume574,584 shsAverage Volume1.21 million shsMarket Capitalization$68.73 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get SELLAS Life Sciences Group alerts: Email Address SELLAS Life Sciences Group MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside152.1% Upside$3.00 Price TargetShort InterestHealthy13.37% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.55) to ($0.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.85 out of 5 starsMedical Sector527th out of 910 stocksPharmaceutical Preparations Industry242nd out of 426 stocks 3.5 Analyst's Opinion Consensus RatingSELLAS Life Sciences Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageSELLAS Life Sciences Group has only been the subject of 1 research reports in the past 90 days.Read more about SELLAS Life Sciences Group's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted13.37% of the outstanding shares of SELLAS Life Sciences Group have been sold short.Short Interest Ratio / Days to CoverSELLAS Life Sciences Group has a short interest ratio ("days to cover") of 8.4.Change versus previous monthShort interest in SELLAS Life Sciences Group has recently decreased by 27.51%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSELLAS Life Sciences Group does not currently pay a dividend.Dividend GrowthSELLAS Life Sciences Group does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SLS. Previous Next 2.7 News and Social Media Coverage News SentimentSELLAS Life Sciences Group has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for SELLAS Life Sciences Group this week, compared to 2 articles on an average week.Search InterestOnly 7 people have searched for SLS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added SELLAS Life Sciences Group to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SELLAS Life Sciences Group insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.60% of the stock of SELLAS Life Sciences Group is held by insiders.Percentage Held by InstitutionsOnly 17.38% of the stock of SELLAS Life Sciences Group is held by institutions.Read more about SELLAS Life Sciences Group's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for SELLAS Life Sciences Group are expected to grow in the coming year, from ($0.55) to ($0.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SELLAS Life Sciences Group is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SELLAS Life Sciences Group is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about SELLAS Life Sciences Group's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About SELLAS Life Sciences Group Stock (NASDAQ:SLS)SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. The company is headquartered in New York, New York.Read More SLS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SLS Stock News HeadlinesAugust 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for SELLAS Life Sciences Amid Strong Financial Position and Promising Clinical TrialsAugust 15, 2024 | seekingalpha.comTriSalus Life Sciences, Inc. (TLSI) Q2 2024 Earnings Call TranscriptSeptember 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.August 14, 2024 | finanznachrichten.deSELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 13, 2024 | markets.businessinsider.comSLS Stock Earnings: SELLAS Life Sciences Gr Beats EPS for Q2 2024August 13, 2024 | globenewswire.comSELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 6, 2024 | globenewswire.comSELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell LymphomasAugust 5, 2024 | lse.co.ukSellas Life Sciences Group Share ChatSeptember 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.August 5, 2024 | ca.finance.yahoo.comSLS Aug 2024 0.500 callJuly 31, 2024 | finance.yahoo.comSELLAS Life Sciences Announces $21.0 Million Registered Direct Offering Priced at a Premium to MarketJuly 31, 2024 | msn.comSELLAS Life Sciences announces $21M registered direct offeringJuly 27, 2024 | finance.yahoo.comCitius Pharmaceuticals Inc (47N.BE)July 25, 2024 | yahoo.comSLS Core Stage ArrivesJuly 22, 2024 | msn.comConnect Life Sciences Strengthens Board with Two New AppointmentsJuly 16, 2024 | globenewswire.comSELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid LeukemiaJuly 8, 2024 | globenewswire.comSELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid LeukemiaJune 24, 2024 | globenewswire.comSELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic LeukemiaSee More Headlines Receive SLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SELLAS Life Sciences Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2024Today9/07/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SLS CUSIPN/A CIK1390478 Webwww.sellaslifesciences.com Phone(646) 200-5278Fax441-400-2875Employees10Year FoundedN/APrice Target and Rating Average Stock Price Target$3.00 High Stock Price Target$3.00 Low Stock Price Target$3.00 Potential Upside/Downside+152.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,340,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-17,349.61% Return on Assets-255.78% Debt Debt-to-Equity RatioN/A Current Ratio1.02 Quick Ratio1.02 Sales & Book Value Annual Sales$1 million Price / Sales68.73 Cash FlowN/A Price / Cash FlowN/A Book Value($0.25) per share Price / Book-4.76Miscellaneous Outstanding Shares57,755,000Free Float56,831,000Market Cap$68.73 million OptionableNot Optionable Beta2.39 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Angelos M. Stergiou M.D. (Age 48)ScD h.c., Founder, President, CEO & Director Comp: $921.99kMr. John Thomas Burns CPA (Age 39)Senior VP & CFO Comp: $338.45kMs. Stacy E. YeungVP, Associate General Counsel & Head of ComplianceDr. Dragan Cicic M.D. (Age 61)MBA, Senior Vice President of Clinical Development Comp: $466.43kMr. Andrew ElnatanVP and Head of Regulatory Affairs, Chemistry, Manufacturing and Controls & QualityKey CompetitorsNeos TherapeuticsNASDAQ:NEOSCorrevio PharmaNASDAQ:CORVMillendo TherapeuticsNASDAQ:MLNDInozyme PharmaNASDAQ:INZYSolid BiosciencesNASDAQ:SLDBView All CompetitorsInstitutional OwnershipRenaissance Technologies LLCBought 32,446 shares on 8/9/2024Ownership: 0.056%View All Institutional Transactions SLS Stock Analysis - Frequently Asked Questions How have SLS shares performed this year? SELLAS Life Sciences Group's stock was trading at $1.06 on January 1st, 2024. Since then, SLS shares have increased by 12.3% and is now trading at $1.19. View the best growth stocks for 2024 here. How were SELLAS Life Sciences Group's earnings last quarter? SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) announced its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.03. When did SELLAS Life Sciences Group's stock split? SELLAS Life Sciences Group's stock reverse split on the morning of Friday, November 8th 2019. The 1-50 reverse split was announced on Wednesday, November 6th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 7th 2019. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. Who are SELLAS Life Sciences Group's major shareholders? SELLAS Life Sciences Group's top institutional shareholders include Renaissance Technologies LLC (0.06%). View institutional ownership trends. How do I buy shares of SELLAS Life Sciences Group? Shares of SLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SLS) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SELLAS Life Sciences Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SELLAS Life Sciences Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SLS Stock Alerts